Feasibility of immuno-PCR technology platforms as an ultrasensitive tool for the detection of anti-drug antibodies

Bioanalysis

Volumn 7, Issue 3, 2015, Pages 285-294

  Jani, Darshana ^a   Savino, Edward ^a   Goyal, Jaya ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; MONOCLONAL ANTIBODY; ANTIBODY; DRUG; HYBRID PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNO POLYMERASE CHAIN REACTION; IMMUNOGENICITY; INTERMETHOD COMPARISON; MEASUREMENT PRECISION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BIOLOGICAL THERAPY; BLOOD; FEASIBILITY STUDY; HUMAN; IMMUNOLOGY; LIMIT OF DETECTION; LUMINESCENCE; PROCEDURES;

ANTIBODIES; BIOLOGICAL THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; HUMANS; LIMIT OF DETECTION; LUMINESCENT MEASUREMENTS; PHARMACEUTICAL PREPARATIONS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS;

EID: 84923365249     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.245     Document Type: Article

References (16)

1. Adler M, Wacker R, Niemeyer CM. A real-Time immune-PCR assay for routine ultrasensitive quantification of proteins. Biochem. Biophys. Res. Commun. 308(2), 240-250 (2003).
2. Adler M, Wacker R, Niemeyer CM. Sensitivity by combination: immuno-PCR and related technologies. Analyst 133(6), 702-718 (2008).
3. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 28(11), 482-490 (2007).
4. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Medicinal Products for Human Use (CHMP), Biosimilar Medicinal Products Working Party (BMWP), 2009. Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. EMEA/CHMP/BMWP/114720/2009. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003910.pdf
5. Koren E. Risk based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1-9 (2008).
6. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for the detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
7. US Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research, 2009. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ UCM192750.pdf
8. Neyer L, Hiller J, Gish K, Keller S, Caras I. Confirming human antibody responses to a therapeutic monoclonal antibody using statistical approach. J. Immunol. Methods 315, 80-87 (2006).
9. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004).
10. Niemeyer CM, Adler M, Wacker R. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol. 23(4), 208-216 (2005).
11. Niemeyer CM, Adler M, Wacker R. Detecting antigens by quantitative immuno-PCR. Nat. Protoc. 2(8), 1918-1930 (2007).
12. Sano T, Smith CL, Cantor CR. Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates. Science 258(5079), 120-122 (1992).
13. Spengler M, Adler M, Jonas A, Niemeyer CM. Immuno-PCR assays for immunogenicity testing. Biochem. Biophys. Res. Commun. 387(2), 278-282 (2009).
14. Stein KE. Immunogenicity: concepts/issues/concerns. Dev. Biol. (Basel) 109, 15-23 (2002).
15. Shankar G, Shores E, Wagner C et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24(6), 274-280 (2006).
16. Applied-Biosystems. User Guide-ABI Prism 7900HT Sequence Detection System. Applied Biosystems, CA, USA (2001).